Loading...

Tenax Therapeutics

DB:YBOC
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YBOC
DB
$10M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Tenax Therapeutics has significant price volatility in the past 3 months.
YBOC Share Price and Events
7 Day Returns
-13.2%
DB:YBOC
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-71.2%
DB:YBOC
-9.2%
DE Biotechs
-6.7%
DE Market
YBOC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tenax Therapeutics (YBOC) -13.2% -21.8% 34.1% -71.2% -97.2% -98.1%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • YBOC underperformed the Biotechs industry which returned -9.2% over the past year.
  • YBOC underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
YBOC
Industry
5yr Volatility vs Market
Related Companies

YBOC Value

 Is Tenax Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tenax Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tenax Therapeutics.

DB:YBOC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:YBOC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:YBOC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tenax Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:YBOC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -12.40 Analyst x1 -11.48
2020 -10.40 Analyst x1 -8.91
2021 -10.90 Analyst x1 -8.65
2022 16.90 Analyst x1 12.42
2023 44.10 Analyst x1 30.00
2024 52.17 Est @ 18.31% 32.86
2025 58.90 Est @ 12.89% 34.35
2026 64.25 Est @ 9.09% 34.69
2027 68.38 Est @ 6.43% 34.18
2028 71.51 Est @ 4.57% 33.09
Present value of next 10 years cash flows $182.55
DB:YBOC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $71.51 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$921.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $921.09 ÷ (1 + 8.01%)10
$426.29
DB:YBOC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $182.55 + $426.29
$608.83
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $608.83 / 6.15
$98.93
DB:YBOC Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:YBOC represents 0.84311x of NasdaqCM:TENX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.84311x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 98.93 x 0.84311
€83.41
Value per share (EUR) From above. €83.41
Current discount Discount to share price of €1.41
= -1 x (€1.41 - €83.41) / €83.41
98.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Tenax Therapeutics is available for.
Intrinsic value
>50%
Share price is €1.41 vs Future cash flow value of €83.41
Current Discount Checks
For Tenax Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Tenax Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Tenax Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tenax Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tenax Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:YBOC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-9.04
NasdaqCM:TENX Share Price ** NasdaqCM (2019-04-18) in USD $1.67
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tenax Therapeutics.

DB:YBOC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:TENX Share Price ÷ EPS (both in USD)

= 1.67 ÷ -9.04

-0.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tenax Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Tenax Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Tenax Therapeutics's expected growth come at a high price?
Raw Data
DB:YBOC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
56.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tenax Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tenax Therapeutics's assets?
Raw Data
DB:YBOC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.10
NasdaqCM:TENX Share Price * NasdaqCM (2019-04-18) in USD $1.67
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:YBOC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:TENX Share Price ÷ Book Value per Share (both in USD)

= 1.67 ÷ 3.10

0.54x

* Primary Listing of Tenax Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tenax Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Tenax Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Tenax Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

YBOC Future Performance

 How is Tenax Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tenax Therapeutics expected to grow at an attractive rate?
  • Tenax Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Tenax Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Tenax Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:YBOC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:YBOC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 56.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:YBOC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:YBOC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 135 67 1
2022-12-31 66 28 1
2021-12-31 0 -11 1
2020-12-31 0 -13 2
2019-12-31 0 -11 2
DB:YBOC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -5 -14
2018-09-30 -6 -6
2018-06-30 -5 -6
2018-03-31 -10 -7
2017-12-31 -12 -9
2017-09-30 -14 -37
2017-06-30 -17 -40
2017-03-31 -17 -42
2016-12-31 -16 -44
2016-09-30 0 -18 -19
2016-06-30 0 -17 -17
2016-03-31 -14 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tenax Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Tenax Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:YBOC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Tenax Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YBOC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.93 2.93 2.93 1.00
2022-12-31 1.40 1.40 1.40 1.00
2021-12-31 -0.76 -0.76 -0.76 1.00
2020-12-31 -1.00 -0.93 -1.06 2.00
2019-12-31 -1.80 -1.80 -1.80 1.00
DB:YBOC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -9.04
2018-09-30 -4.12
2018-06-30 -3.95
2018-03-31 -4.77
2017-12-31 -6.27
2017-09-30 -26.36
2017-06-30 -28.54
2017-03-31 -29.75
2016-12-31 -31.24
2016-09-30 -13.35
2016-06-30 -12.39
2016-03-31 -12.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tenax Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Tenax Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tenax Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

YBOC Past Performance

  How has Tenax Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tenax Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tenax Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Tenax Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tenax Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Tenax Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tenax Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YBOC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -14.14 5.62 1.24
2018-09-30 -5.93 5.32 0.73
2018-06-30 -5.63 5.18 0.62
2018-03-31 -6.74 5.40 1.53
2017-12-31 -8.84 5.68 3.53
2017-09-30 -37.14 6.27 16.51
2017-06-30 -40.18 6.48 16.26
2017-03-31 -41.84 5.93 15.04
2016-12-31 -43.92 6.25 12.98
2016-09-30 -0.05 -18.77 5.20
2016-06-30 -0.05 -17.42 5.36
2016-03-31 -17.52 6.05
2015-12-31 -15.10 5.91
2015-10-31 0.05 -14.41 6.49
2015-07-31 0.05 -14.94 6.84
2015-04-30 0.05 -14.08 6.96
2015-01-31 -0.01 -19.57 14.53
2014-10-31 0.04 -21.15 14.41
2014-07-31 0.10 -23.18 14.24
2014-04-30 0.29 -25.35 13.77
2014-01-31 0.50 -17.69 4.45
2013-10-31 0.68 -15.65 4.11
2013-07-31 1.15 -11.13 3.11
2013-04-30 1.23 -10.37 3.68
2013-01-31 1.13 -10.17 4.28
2012-10-31 1.05 -15.06 4.19
2012-07-31 0.63 -16.43 5.46
2012-04-30 0.42 -15.71 6.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tenax Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Tenax Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tenax Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tenax Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tenax Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

YBOC Health

 How is Tenax Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tenax Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tenax Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tenax Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tenax Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Tenax Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tenax Therapeutics Company Filings, last reported 3 months ago.

DB:YBOC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 11.77 0.00 12.86
2018-09-30 4.94 0.00 4.86
2018-06-30 6.23 0.00 6.41
2018-03-31 8.00 0.00 6.62
2017-12-31 8.88 0.00 7.73
2017-09-30 10.16 0.00 8.53
2017-06-30 11.27 0.00 8.80
2017-03-31 14.11 0.00 12.52
2016-12-31 17.14 0.00 13.28
2016-09-30 46.69 0.00 7.48
2016-06-30 50.89 0.00 9.95
2016-03-31 55.33 0.00 15.77
2015-12-31 60.42 0.00 20.19
2015-10-31 63.93 0.00 21.68
2015-07-31 67.37 0.05 21.31
2015-04-30 70.43 0.10 17.13
2015-01-31 75.36 0.15 17.07
2014-10-31 77.59 0.00 22.58
2014-07-31 81.54 0.02 26.12
2014-04-30 82.89 0.35 58.32
2014-01-31 30.30 0.37 6.34
2013-10-31 2.85 0.23 2.54
2013-07-31 1.13 3.43 4.07
2013-04-30 -1.78 3.05 0.78
2013-01-31 -1.60 2.68 0.83
2012-10-31 -0.06 2.61 1.51
2012-07-31 -0.64 3.83 2.69
2012-04-30 -0.35 2.67 1.88
  • Tenax Therapeutics has no debt.
  • Tenax Therapeutics has no debt compared to 5 years ago when it was 1.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Tenax Therapeutics has sufficient cash runway for 2.3 years based on current free cash flow.
  • Tenax Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -29.7% each year.
X
Financial health checks
We assess Tenax Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tenax Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

YBOC Dividends

 What is Tenax Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tenax Therapeutics dividends.
If you bought €2,000 of Tenax Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tenax Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tenax Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:YBOC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:YBOC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tenax Therapeutics has not reported any payouts.
  • Unable to verify if Tenax Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tenax Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tenax Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Tenax Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tenax Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tenax Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

YBOC Management

 What is the CEO of Tenax Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony DiTonno
COMPENSATION $59,376
AGE 70
TENURE AS CEO 0.8 years
CEO Bio

Mr. Anthony A. DiTonno, also known as Tony, has been Chief Executive Officer of Tenax Therapeutics, Inc. since June 1, 2018. From January 2013 until May 31, 2018, Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc. He has also been successful in gaining regulatory approvals in both the United States and European Union. Mr. DiTonno has over 20 years of senior leadership experience spanning the pharmaceutical and medical device industries. He served as the President and Chief Executive Officer of Neurogesx Inc., from April 2003 to December 31, 2011. From October 2000 to November 2002, he served as an Executive Vice President of Sales & Marketing at Enteric Medical Technologies, Inc. Prior to Enteric, he served as the Chief Executive Officer of LifeSleep Systems, Inc. from 1997 to 2000 and also served as its President. He served as Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. From 1989 to 1997, Mr. DiTonno served as Vice President and General Manager of Oclassen Pharmaceuticals, Inc. He also served Vice President of Sales and Marketing for Oclassen. He has also served various sales and marketing positions at Rorer Pharmaceuticals (Aventis) and Wyeth Laboratories. He held a variety of positions of increasing responsibility at Rorer Group, Inc. (Rhône Poulenc Rorer) and Wyeth Laboratories. He has been a Director of Tenax Therapeutics, Inc. since December 15, 2011. He serves as an Executive Director of Neurogesx, Inc. Mr. DiTonno earned a BS Degree in business administration from St. Joseph's University and an MBA from Drexel University, both in Philadelphia, Pennsylvania.

CEO Compensation
  • Tony's compensation has been consistent with company performance over the past year.
  • Tony's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Tenax Therapeutics management team in years:

5.8
Average Tenure
64
Average Age
  • The average tenure for the Tenax Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Tony DiTonno

TITLE
CEO & Director
COMPENSATION
$59K
AGE
70
TENURE
0.8 yrs

Michael Jebsen

TITLE
President & CFO
COMPENSATION
$596K
AGE
47

John Kelley

TITLE
Consultant
COMPENSATION
$987K
AGE
64
TENURE
2 yrs

Nancy J. Hecox

TITLE
Executive VP of Legal Affairs
TENURE
9.5 yrs

Maria Tomargo

TITLE
Assistant Vice President of Marketing & Sales

Bob Diegelmann

TITLE
Head of New Wound Care Division
TENURE
10.6 yrs

Doug Randall

TITLE
Executive Vice President of Commercial & Business Operations

Douglas Hay

TITLE
Executive Vice President of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Tenax Therapeutics board of directors in years:

5
Average Tenure
67.5
Average Age
  • The tenure for the Tenax Therapeutics board of directors is about average.
Board of Directors

Ron Blanck

TITLE
Chairman
COMPENSATION
$70K
AGE
77
TENURE
7.6 yrs

Tony DiTonno

TITLE
CEO & Director
COMPENSATION
$59K
AGE
70
TENURE
7.3 yrs

Ross Bullock

TITLE
Chairman of Medical Advisory Board

Gerry Proehl

TITLE
Independent Director
COMPENSATION
$61K
AGE
59
TENURE
5 yrs

Jim Mitchum

TITLE
Independent Director
COMPENSATION
$64K
AGE
65
TENURE
3.6 yrs

Stuart Rich

TITLE
Chairman of Scientific Advisory Board
TENURE
1.2 yrs

Joseph Watson

TITLE
Member of Medical Advisory Board

Robert Sladen

TITLE
Member of Medical Advisory Board

Cyril Mazer

TITLE
Member of Medical Advisory Board

Abe DeAnda

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Tenax Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tenax Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

YBOC News

Simply Wall St News

YBOC Company Info

Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Details
Name: Tenax Therapeutics, Inc.
YBOC
Exchange: DB
Founded: 1967
$9,143,223
6,154,434
Website: http://www.tenaxthera.com
Address: Tenax Therapeutics, Inc.
ONE Copley Parkway,
Suite 490,
Morrisville,
North Carolina, 27560,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM TENX Common Stock Nasdaq Capital Market US USD 16. Mar 1993
DB YBOC Common Stock Deutsche Boerse AG DE EUR 16. Mar 1993
Number of employees
Current staff
Staff numbers
10
Tenax Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:32
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.